CLIAMS:CLAIMS

1. A system for identifying glucose metabolism disorder in a patient, said system comprising:
a plurality of detection modules;
a plurality of administering modules configured to be in communication with corresponding detection module; and
an output module, wherein said plurality of detection modules, administering modules and output module further configured to:
measure a first blood glucose level using a first detection module from said plurality of detection modules; and
provide a condition of said patient as having at least one of an insulin sensor problem, production unit problem, glucose sensor unit problem, insulin sensor over sensitivity problem, glucose sensor over sensitivity problem or a production unit over sensitivity problem by analyzing said measured first glucose level using said output module.
2. The system as in claim 1, wherein said system is further configured to provide condition of said patient as having insulin sensor problem by:
communicating with a first administering module of said administering modules, if the first detection module detects that the first blood glucose level is more than a set threshold value of glucose;
administering insulin to the patient using the first administering module;
detecting a second blood glucose level after a preset time from said administering of the insulin using a second detection module from said plurality of detection modules; and
providing condition of said patient as having said insulin sensor problem if the second glucose level measured by said second detection module is more than said set threshold value of glucose, using said output module.
3. The system as in claim 2, wherein said system is configured to provide condition of said patient as having said production unit problem by:
measuring an endogenous insulin level if the second blood glucose level measured by said second detection module is one of equal or less than said set threshold value of glucose using a third detection module;
comparing said endogenous insulin level with a measured first insulin value; and
providing condition of said patient as having said production unit problem if the endogenous insulin measured by said third detection module is more than said first insulin value, using said output module.
4. The system as in claim 3 is further configured to provide condition of said patient as having glucose sensor unit problem if the endogenous insulin measured by said third detection module is one of equal or less than said measured first insulin value, using said output module.
5. The system as in claim 1, wherein said system is further configured to provide condition of said patient as having said insulin sensor over sensitivity problem by:
administering glucose if the measured first blood glucose level is one of equal or lesser than said set threshold value of glucose using a second administering module of said plurality of administering modules;
detecting a third blood glucose level after a preset time from said administering of the glucose using a fourth detection module of said detection units; and
providing a condition of said patient as having said insulin sensor over sensitivity problem if the third blood glucose level measured by said fourth detection module is less than said set threshold value of glucose and a measured first insulin value lesser than a set threshold value of insulin, using said output module.
6. The system as in claim 5, wherein said system is further configured to provide condition of said patient as having said glucose sensor over sensitivity problem by:
administering glucose if the third blood glucose level measured by said fourth detection module is less than said set threshold value of glucose and a measured insulin value is one of equal or more than a set threshold value of insulin using a third administering module;
measuring a second insulin value after a preset time from said administering of the glucose using a fifth detection module; and
providing condition of said patient as having said glucose sensor over sensitivity problem if the measured second insulin value by said fifth detection module is more than said first insulin value, using said output module.
7. The system as in claim 6, wherein said system is further configured to provide condition of said patient as having said production unit over sensitivity problem if the measured second insulin value by said fifth detection module is equal or less than said first insulin value, using said output module.
8. A method for identifying glucose metabolism disorder in a patient, said method comprising:
measuring a first blood glucose level using a first detection module; and
providing a condition of said patient as having at least one of an insulin sensor problem , production unit problem, glucose sensor unit problem, insulin sensor over sensitivity problem, glucose sensor over sensitivity problem or a production unit over sensitivity problem by analyzing said measured glucose level using an output module.
9. The method as in claim 8, wherein said providing condition of the patient as having insulin sensor problem further comprises:
comparing said measured first blood glucose level with a set threshold value of glucose;
administering insulin using a first administering module if said measured glucose value is more than said set threshold value of glucose;
detecting a second blood glucose level using a second detection module after said administering of the insulin; and
providing condition of said patient as having insulin sensor problem using said output module if the second blood glucose level is more than said set threshold value of glucose.
10. The method as in claim 9, wherein said providing condition of the patient as having at least one of said production unit problem or glucose sensor unit problem further comprises:
measuring an endogenous insulin level using a third detection module if said second blood glucose level is one of equal or less than said set threshold value of glucose;
comparing said endogenous insulin level with a measured first insulin value;
providing condition of the patient as having said production unit problem if the endogenous insulin level is more than said measured first insulin value; and
providing condition of the patient as having said glucose sensor unit problem if the endogenous insulin level is one of equal or less than said measured first insulin value.
11. The method as in claim 8, wherein said providing condition of said patient as having insulin sensor over sensitivity problem further comprises:
comparing said measured first blood glucose level with a set threshold value of glucose;
administering glucose using a second administering module if the measured blood glucose level is one of equal or lesser than said set threshold value of glucose;
detecting a third blood glucose level using a fourth detecting module after said administering of the glucose; and
providing condition of said patient as having said insulin sensor over sensitivity problem using said output module if the third blood glucose level is less than said set threshold value of glucose and a measured first insulin value lesser than a set threshold value of insulin.
12. The method as in claim 11, wherein providing condition of said patient as having at least one of said glucose sensor over sensitivity problem or secretion unit over sensitivity problem further comprises:
administering glucose if the measured third blood glucose level is less than said set threshold value of glucose and a measured first insulin value is one of equal or more than a set threshold value of insulin, using a third administering module;
measuring a second insulin value using a fifth detection module after said administering of the glucose;
providing condition of said patient as having said glucose sensor over sensitivity problem using said output module if the measured second insulin value is more than said first insulin value; and
providing condition of said patient as having said secretion unit over sensitivity problem using said output module if the measured second insulin value is one of equal or less than said first insulin value.

Dated: 02-07-2013

Signature:

Nishant Kewalramani
( Patent Agent)
,TagSPECI:FORM 2
The Patent Act 1970
(39 of 1970)
&
The Patent Rules, 2005
COMPLETE SPECIFICATION
(SEE SECTION 10 AND RULE 13)

TITLE OF THE INVENTION

“SYSTEM AND METHOD FOR IDENTIFICATION AND MANAGEMENT OF GLUCOSE METABOLISM DISORDER”
APPLICANTS:
Name : HCL Technologies Limited
Nationality : Indian
Address : HCL Technologies Ltd
AMB 3.64-66,South Phase,II Main road,
Ambattur Industrial estate,Chennai-58
The following Specification particularly describes and ascertains the nature of this invention and the manner in which it is to be performed:

FIELD OF INVENTION
[001] The embodiments herein relate to data analysis and, more particularly, to identify the glucose metabolism disorder in a patient’s body.

BACKGROUND
[002] The glucose metabolism in body is regulated by a variety of hormones with insulin being the most important. Once a meal is taken, the glucose level in the blood streams increases. The blood glucose levels, if it goes beyond a certain level passes through the GLUT 4 transporter on the surface of beta cells of the pancreas which in turn triggers the production and release of insulin into the blood stream. Hence, the GLUT 4 acts as the glucose sensor of the pancreas. The insulin is produced by the transcription and the subsequent protein synthesis of insulin molecules in the beta cells of the pancreas. Hence this component can be equated to a production unit. Insulin is secreted by the opening up of intracellular vesicles into the blood stream. The insulin sensors are present in all the cells of the body but the cells in liver and muscles are the most important. The insulin thus released is sensed by these insulin sensors which in turn controls the glucose metabolism. Insulin promotes the uptake of glucose by the cells of the body and hence reduces the blood glucose levels. Once the blood glucose levels falls, it reduces the trigger to release insulin and hence the blood glucose is stabilized. This requires the following components for the whole system to perform correctly: Glucose sensor at the pancreatic beta cells, Production unit for insulin, Insulin storage and releasing mechanism from the beta cells into the blood, Insulin sensors in the peripheral cells of the body.
[003] What is needed therefore is a system and method that identifies the exact reason for the glucose metabolism disorder present in patient’s body.
SUMMARY
[004] In view of the foregoing, an embodiment herein provides a system for identifying glucose metabolism disorder in a patient, the system comprising a plurality of detection modules; a plurality of administering modules configured to be in communication with corresponding detection module; and an output module, wherein the plurality of detection modules, administering modules and output module further configured to measure a first blood glucose level using a first detection module from the plurality of detection modules; and provide a condition of the patient as having at least one of an insulin sensor problem, production unit problem, glucose sensor unit problem, insulin sensor over sensitivity problem, glucose sensor over sensitivity problem or a production unit over sensitivity problem by analyzing the measured first glucose level using the output module.
[005] Embodiments further disclose a method for identifying glucose metabolism disorder in a patient, the method comprising measuring a first blood glucose level using a first detection module; and providing a condition of the patient as having at least one of an insulin sensor problem , production unit problem, glucose sensor unit problem, insulin sensor over sensitivity problem, glucose sensor over sensitivity problem or a production unit over sensitivity problem by analyzing the measured glucose level, using an output module.
[006] These and other aspects of the embodiments herein will be better appreciated and understood when considered in conjunction with the following description and the accompanying drawings.

BRIEF DESCRIPTION OF THE FIGURES
[007] The embodiments herein will be better understood from the following detailed description with reference to the drawings, in which:
[008] FIG. 1 illustrates a block diagram that shows various components of Glucose metabolism disorder identification system, as disclosed in the embodiments herein;
[009] FIG. 2 is a flow diagram which shows various steps involved in the process of identifying exact reason for the glucose metabolism disorder in the patient body using Glucose metabolism disorder identification system, as disclosed in the embodiments herein; and
[0010] FIG. 3 is a flow diagram which shows various steps involved in the process of analyzing the patient data in order to identify the exact reason for glucose metabolism disorder, as disclosed in the embodiments herein.

DETAILED DESCRIPTION OF INVENTION
[0011] The embodiments herein and the various features and advantageous details thereof are explained more fully with reference to the non-limiting embodiments that are illustrated in the accompanying drawings and detailed in the following description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein.
[0012] The embodiments herein disclose a system and method for identifying the exact reason for glucose metabolism disorder in the patient’s body by using a Glucose metabolism disorder identification system. Referring now to the drawings, and more particularly to FIGS. 1 through 3, where similar reference characters denote corresponding features consistently throughout the figures, there are shown embodiments.
[0013] FIG. 1 illustrates a block diagram that shows various components of Glucose metabolism disorder identification system, as disclosed in the embodiments herein. The Glucose metabolism disorder identification system further comprises of an Input/Output interface 101, a plurality of detection modules 102, a plurality of administering modules 103, a data analysis module 104, a timer module 105 and a memory module 106.
[0014] The Input/Output (I/O) module 101 can be any type of commonly available input/output device which is capable of fetching input from user by providing a suitable interface such as keyboard, mouse, and touch screen and so on. By using this I/O module 101, the user can manually provide any required input information such as pre-defined threshold values, control commands to customize the timer options of Glucose metabolism disorder identification system and so on. The I/O module 101 receives the information regarding patient condition which is further provided to the user (may be doctor/nurse/ medical practitioner) by using suitable user interface such as a print out or in a display screen.
[0015] The plurality of detection modules 102 (first detection module, second detection module, third detection module and so on) may be any devices such as a Continuous Glucose Monitoring device (CGM), Insulin measurement device, and so on that are capable of measuring blood glucose and insulin levels present in the patient body. Further, the plurality of administering modules 103 (first administering module, second administering and so on) may be any devices which are capable of infusing or injecting medication such as glucose or insulin into patient’s body and is also capable of controlling the insulin as well as glucose flow while injecting into patient’s blood stream. Furthermore, the Glucose metabolism disorder identification system makes accurate identification of glucose metabolism disorder present in the patient body by analyzing the patient data at specified intervals of time by using timer module 105.
[0016] The patient data which is collected from various detection modules 102 is delivered to data analysis module 104 for further analysis. The data analysis module 104 further analyzes the patient data by using predefined threshold levels which are configured with the Glucose metabolism disorder identification system by the user. In an embodiment, the memory module 106 stores all the necessary pre-defined threshold values and control commands which are necessary to analyze the patient data. The ‘Pre-defined threshold levels’ are the mean normal blood glucose levels which are present in humans normally. For example, the mean normal blood glucose level in humans is about 5.5 mM (5.5 mmol/L or 100 mg/dL, i.e. milligrams/deciliter). Further, the timer module 105 can be used to collect the patient data by using various detection modules 102 at desired time intervals.
[0017] FIG. 2 is a flow diagram which shows various steps involved in the process of identifying exact reason for the glucose metabolism disorder in the patient body using Glucose metabolism disorder identification system, as disclosed in the embodiments herein. In order to identify the exact reason for glucose metabolism disorder in the patient body, initially the current blood glucose level and insulin values of the patient should be known. Hence the current patient parameters such as blood glucose levels and insulin value are measured (202) by using detection modules 102 which are connected to patient’s body. Further, the data analysis module 104 of Glucose metabolism disorder identification system fetches this patient data and analyzes (204) the data by using pre-defined threshold levels and control commands present in memory module 106. Now, depending on the analyzed result, administering module 103 performs necessary action and finally the exact reason for glucose metabolism disorder is identified (206). The various actions in method 200 may be performed in the order presented, in a different order or simultaneously. Further, in some embodiments, some actions listed in FIG. 2 may be omitted.
[0018] FIG. 3 is a flow diagram which shows various steps involved in the process of analyzing the patient data in order to identify the exact reason for glucose metabolism disorder, as disclosed in the embodiments herein. Initially, the data analysis module 104 fetches (302) a ‘first blood glucose level’ and ‘first insulin value’ from first detection module 102 which is connected to patient’s body. Let us consider the measured (304) first insulin value as ‘x’. Now, the analysis of patient data stars by data analysis module 104 which detects (306) whether the patient has high or normal/low blood glucose level. This can be done by comparing the measured ‘first blood glucose level’ with a set pre-defined threshold value. For example, the mean normal blood glucose level in humans is about 5.5 mM (5.5 mmol/L or 100 mg/dL, i.e. milligrams/deciliter). This blood glucose levels for those without diabetes should be below 125 mg/dL. If the measured blood glucose levels are outside the normal range, then this may be an indicator of a glucose metabolism disorder.
[0019] If the measured ‘first blood glucose level’ is more than the set pre-defined threshold value, then a first administering module 103 injects exogenous insulin (308) into the patient blood streams. After certain amount of time (say ?T1), a second detection module 102 collects current ‘second blood glucose level’ present in the patient’s body. Further, this measured ‘second blood glucose level’ is send to data analysis module 104 which decides (310) whether the second blood glucose level as high/low or normal by comparing the measured second blood glucose level with the set threshold value of glucose. If the ‘second blood glucose level’ is more than said set threshold value, the data analysis module 104 confirms the disorder with insulin sensors (312) present in the patient’s body. Further, if the measured ‘second blood glucose level’ is equal or less than the set threshold value, then a third detection module 102 measures (314) the current ‘endogenous insulin value’ present in the patient’s body. Furthermore, if the measured ‘endogenous insulin value’ is equal or less than the ‘first insulin value’, the data analysis module 104 confirms the disorder with glucose sensor units present in patient’s body. The difference (316) between the ‘first insulin value’ (x) and measured ‘endogenous insulin value’ is calculated. For example, let us consider the value of measured endogenous value as ‘y’ then the difference ‘x-y’ is calculated. If this value results in zero or negative, it indicates that there is problem (320) with glucose sensor units present in the patient’s body. Further, the disorder (318) can be identified with production unit of insulin if the calculated difference results in positive integer.
[0020] Further, if the first detection module 102 detects the measured ‘first blood glucose level’ (306) as equal or lesser than the set threshold value, then a second administration module 103, injects (322) the glucose into patient’s body till the blood glucose level reaches high value. After some pre-defined time interval (say ?T2), a forth detection module 102 measures the current blood glucose level of patient i.e., ‘third blood glucose level’. Now, the data analysis module 104 decide (324) whether the measured ‘third blood glucose level’ is high/low or normal by comparing it with the set threshold blood glucose value. If the measured value is in normal range, then the body glucose metabolism is functioning normally (326). If the measured ‘third blood glucose level’ is high, then the step from 308 will be performed again to find whether the disorder lies in insulin sensor unit or glucose sensor unit or production units present in patient’s body. Further, if the measured ‘third blood glucose level’ is less than the set threshold value, the data analysis module 104 compares the ‘first insulin value’ (x) (328) with set threshold value of insulin. If the ‘first insulin value’ (x) is less than the set threshold value of insulin, then the disorder is due to over sensitivity of insulin sensor (330) present in the patient’s body. Further, if the ‘first insulin value’ measured is more than or equal to the set threshold value of insulin, a third administering module 103 injects exogenous glucose (332) into the blood streams of patient’s body. Further, a fifth detection module 102 detects (334) the current value of insulin i.e., a ‘second insulin value’ after some predefined time (say ?T3). Let the value measured as ‘z’. Further more, the difference (436) between the ‘first insulin value’ (x) and ‘second measured insulin value’ (z) i.e., x-z is calculated. If the calculated difference results in a negative integer (i.e., if the measured second insulin value is more than the first insulin value), then disorder may be due to the over sensitivity (338) of glucose sensor. Further, if the calculated difference results in a positive integer or zero (i.e., if the measured second insulin value is less than or equal to the first insulin value), then disorder may be due to the over sensitivity (338) of glucose sensor otherwise the disorder in glucose metabolism may be due to over sensitivity (340) of production unit present in the patient’s body. The various actions in method 300 may be performed in the order presented, in a different order or simultaneously. Further, in some embodiments, some actions listed in FIG. 3 may be omitted.
[0021] The embodiments disclosed herein can be implemented through at least one software program running on at least one hardware device and performing network management functions to control the network elements. The network elements shown in Fig. 1 include blocks which can be at least one of a hardware device, or a combination of hardware device and software module.
[0022] The embodiment disclosed herein specifies a system for accurate identification of glucose metabolism disorder present in the patient body. The mechanism allows identification of exact reason for disorder in the patient’s body by analyzing the patient data and providing a system thereof. Therefore, it is understood that the scope of the protection is extended to such a program and in addition to a computer readable means having a message therein, such computer readable storage means contain program code means for implementation of one or more steps of the method, when the program runs on a server or mobile device or any suitable programmable device. The method is implemented in a preferred embodiment through or together with a software program written in e.g. Very high speed integrated circuit Hardware Description Language (VHDL) another programming language, or implemented by one or more VHDL or several software modules being executed on at least one hardware device. The hardware device can be any kind of device which can be programmed including e.g. any kind of computer like a server or a personal computer, or the like, or any combination thereof, e.g. one processor and two FPGAs. The device may also include means which could be e.g. hardware means like e.g. an ASIC, or a combination of hardware and software means, e.g. an ASIC and an FPGA, or at least one microprocessor and at least one memory with software modules located therein. Thus, the means are at least one hardware means and/or at least one software means. The method embodiments described herein could be implemented in pure hardware or partly in hardware and partly in software. The device may also include only software means. Alternatively, the invention may be implemented on different hardware devices, e.g. using a plurality of CPUs.
[0023] The foregoing description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the claims as described herein.